Shexiang Baoxin pill

DRUG2 trials

Sponsors

Jun Li, Shanghai Hutchison Pharmaceuticals Limited

Conditions

Acute Myocardial Infarction (AMI)Coronary Artery Disease(CAD)Percutaneous Coronary Intervention (PCI)

Phase 4

Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization

Jun LiCoronary Artery Disease(CAD)

Start: 2017-06-30End: 2019-02-28Target: 440Updated: 2017-04-04

Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction

Not yet recruitingNCT07153744

Shanghai Hutchison Pharmaceuticals LimitedAcute Myocardial Infarction (AMI), Percutaneous Coronary Intervention (PCI)

Start: 2025-09-01End: 2029-12-31Target: 9588Updated: 2025-09-04

Related Papers

Efficacy and safety of the Shexiang Baoxin Pill for the treatment of coronary artery disease not amenable to revascularisation: study protocol for a randomised, placebo-controlled, double-blinded trial

BMJ Open2018-02-0113 citations